Hvsen Biotech(300871.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
Hvsen Biotech
300871.SZ
Wuhan Hvsen Biotechnology Co.,Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company offers tylvalosin tartrate powders and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products. It produces various veterinary drug products of raw materials and preparations, as well as traditional Chinese medicines extractives.
2.788 T
300871.SZMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
B
PharmaceuticalsIndustry
Industry Ranking51/215
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE14.94%A
    • Profit Margin16.45%A
    • Gross Margin35.51%C
  • Growth ScoreA
    • Revenue YoY24.98%A
    • Net Profit YoY602.71%A
    • Total Assets YoY6.63%B
    • Net Assets YoY43.09%A
  • Cash ScoreB
    • Cash Flow Margin81.41%C
    • OCF YoY24.98%A
  • Operating ScoreC
    • Turnover0.55C
  • Debt ScoreB
    • Gearing Ratio30.18%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Hvsen Biotech: Invests 1 billion yuan to build a synthetic biology manufacturing project in Xinjiang

    36Kr·
    SZ
    300871
    -0.51%
    36Kr·
    SZ
    300871
    -0.51%

    Hvsen Biotech released its performance for the first three quarters, with a net profit attributable to the parent company of 188 million yuan, an increase of 494.28%

    Zhitong·
    SZ
    300871
    -0.51%
    Zhitong·
    SZ
    300871
    -0.51%

    Hvsen Biotech: Subsidiary "Yinqiao Lanjin Oral Solution" Obtains New Veterinary Drug Registration Certificate

    Zhitong·
    SZ
    300871
    -0.51%
    Zhitong·
    SZ
    300871
    -0.51%

    Hvsen Biotech: In the first half of this year, it has obtained 7 pet product approvals, greatly expanding its pet product line

    Zhitong·
    SZ
    300871
    -0.51%
    Zhitong·
    SZ
    300871
    -0.51%

    Hvsen Biotech plans to invest CNY 170 million to implement a green equipment technological transformation project for veterinary raw materials

    Zhitong·
    SZ
    300871
    -0.51%
    Zhitong·
    SZ
    300871
    -0.51%
    © 2026 Longbridge｜Disclaimer